Pioglitazone: How Pharmacology Can be used Interchangeably with Mammonology in the Developing Countries?Mina T Kelleni*
Department of Pharmacology, Faculty of Medicine, Minia University, Egypt
- *Corresponding Author:
- Mina T Kelleni
Assistant Lecturer of Pharmacology
Faculty of Medicine, Minia University, Egypt
E-mail: [email protected]
Received date: June 27, 2014; Accepted date: August 07, 2014; Published date: August 16, 2014
Citation: Kelleni MT (2014) Pioglitazone: How Pharmacology Can be used Interchangeably with Mammonology in the Developing Countries? J Diabetes Metab 5:411 doi: 10.4172/2155-6156.1000411
Copyright: © 2014 Kelleni MT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Exporting Pioglitazone either as an active ingredient or as already made trade named packages to the developing countries where many conditions favor carcinogenicity and medical illiteracy of its relationship with urinary bladder carcinoma is so prevalent not only among patients but also among a proportionate sector of health care providers, is nearly the perfect crime of the new millennium.